In Vitro Antiviral Testing

We are happy to test your antiviral compounds in vitro.
The IAR routinely performs testing for antiviral efficacy in vitro. We have a myriad of viruses and models available, including BSL-3, BSL-3+, and select agents. Testing is done by neutral red assays, microscopic CPE assays, plaque reduction assays, and/or virus yield reduction assays. We can also perform mechanism of action studies for you. In addition, we have developed a high throughput assay where we screen up to 300 compounds at one time at a greatly reduced cost.  Please contact Dr. Craig Day (435-512-1592, for details and pricing.

Below is a list of the viruses we have readily available for in vitro screening:

Family Genus Virus Strain
Adenoviridae Mastadenovirus Adenovirus 15 serotypes
Arenaviridae Arenavirus Junin Candid #1 and Romero
Tacaribe TRVL 11573
Pichinde An 4763
Lymphocytic choriomeningitis Armstrong and Clone 13
Bunyavirdae Hantavirus Dobrava Sotkamo
Hantaan 76-118
Sin Nombre SN77734
Andes Chile-9717869
Maporal HV 97021050
Orthobunyavirus La Crosse encephalitis
Phlebovirus Punta Toro Adames
Rift Valley fever MP-12, ZH501
Severe fever thrombocyto. syndrome HB-29
Heartland MO-4
Sandfly fever Naples
Coronaviridae Coronavirus SARS Corona Urbani, Toronto-2, Frankfurt-1, and CuHK-1
Corona Human, rat, and mouse
Transmissible gastroenteritis  
Bovine corona  
Flaviviridae Flavivirus Banzi H336
Dengue Serotypes 2 and 3
Usutu virus South Africa and Austria
West Nile NY WNV and WN02
Yellow Fever 17D
Zika Malaysia  and Uganda
Herpesviridae Simplexvirus Herpes Types 1 and 2
Varicellovirus Bovine herpes  
Orthomyxoviridae  Influenza 30 serotypes pandemic and seasonal H1N1, seasonal H3N2, low-path avian H5N1, high-path avian H5N1, and some oseltamivir-resistant and amantadine-resistant strains
Paramyxoviridae Morbillivirus Measles  
Respirovirus Parainfluenza  
Pneumovirus  Respiratory syncytial Human A and B strains, clinical isolates and bovine
Picornaviridae Enterovirus Coxsackie B1  
Coxsackie B4  
Poliovirus Type 3
Cardiovirus Encephalomyocarditis
Rhinovirus Rhino 100 strains and clinical isolates
Poxviridae Orthopoxvirus Cowpox Brighton
Vaccinia WR and IHD
Reoviridae Reovirus Reo
Rotavirus  Rota Human, simian, and bovine
Rhabdoviridae Vesiculovirus Vesicular stomatitis  
Togaviridae Alphavirus Chikungunya LR06 and S27
Semliki Forest Original
Venezuelan equine encephalitis TC-83 and TrD
Western equine encephalitis California (VR-70)

Antiviral Assay by CPE:

This test is for initial screening of potentially antiviral compounds. The antiviral activity of the compound is evaluated based on the ability of the compound to prevent virus from causing viral cytopathic effects (CPE) in mammalian cell culture. Eight dilutions of test compound are assayed, and the effective antiviral concentration determined by regression analysis. The toxicity of the test compound is determined in parallel. An abbreviated test with only 4 dilutions of compound may be employed to screen large numbers of compounds quickly and at a reduced cost.

Virus Yield Reduction Assay:

This test evaluates the ability of the compound to inhibit virus production in mammalian cell culture. This is a two-step assay where virus is first produced in cultures containing the antiviral substance at varying dilutions, followed later by titration of the samples for virus titer by endpoint dilution in 96-well microplates. Eight dilutions of test compound are assayed, and the effective antiviral concentration determined by regression analysis. This test is normally requested as a follow-up for compounds that demonstrate activity in the CPE assay.

Virucidal Assay:

This assay shows whether a test compound inactivates ("kills") virus outside of cells, or in other words, whether the compound inactivates the virus before infection of the cells. A virucidal compound will appear active in the antiviral assay, but virucidal compounds (e.g. alcohol, sodium hypochlorite, etc.) are normally not considered candidates for antiviral treatment. The assay is performed by incubating virus plus compound for 1 hour (or a length of time requested by the sponsor), followed by determining virus titer by endpoint dilution in 96-well microplates of cells.